After signing up, you'll start to receive regular news updates from us.
NovAliX Enters into Alliance with Kyowa Hakko Kirin
Complete the form below to unlock access to ALL audio articles.
NovAliX SAS has announced that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan.
Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets.
NovAliX will generate novel lead candidates using the broad spectrum of its biophysical capabilities and its medicinal chemistry expertise.
Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.
Stephan Jenn, President of NovAliX, stated, "For NovAliX this drug discovery alliance represents a significant development of our established relation with Kyowa Hakko Kirin. This drug discovery collaboration with a leading Japanese pharmaceutical company also confirms the quality of our discovery platforms and its ability to deliver valuable lead candidates."
